Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBT: 2021-2025

Historic EBT for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$34.4 million.

  • Amylyx Pharmaceuticals' EBT rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.9 million, marking a year-over-year increase of 41.78%. This contributed to the annual value of -$302.1 million for FY2024, which is 656.45% down from last year.
  • Amylyx Pharmaceuticals' EBT amounted to -$34.4 million in Q3 2025, which was up 17.03% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' EBT registered a high of $24.0 million during Q2 2023, and its lowest value of -$118.6 million during Q1 2024.
  • Its 3-year average for EBT is -$32.7 million, with a median of -$35.9 million in 2025.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' EBT soared by 144.55% in 2023, and later plummeted by 8,549.82% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' EBT (Quarterly) stood at -$28.3 million in 2021, then tumbled by 52.51% to -$43.2 million in 2022, then surged by 114.98% to $6.5 million in 2023, then crashed by 689.58% to -$38.2 million in 2024, then skyrocketed by 52.70% to -$34.4 million in 2025.
  • Its EBT stands at -$34.4 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$35.9 million for Q1 2025.